Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of an Oral Vaccine to Prevent Seasonal Influenza

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* In good health as established by medical history, physical examination, and laboratory testing at the time of enrollment.~Exclusion Criteria:~* Positive for H1 influenza by HAI.~* Has had an influenza vaccine in the past 2 years.~* Current history of chronic alcohol consumption and/or illicit and/or recreational drug use.~* History of any confirmed or suspected immunodeficient or immunosuppressive condition~* Positive serology for HIV, HCV, or HBV~* Previous serious reactions to vaccination such as anaphylaxis, respiratory problems, hives, or abdominal pain.~* History of irritable bowel disease or other inflammatory digestive or gastrointestinal conditions that could affect the intended distribution of the vaccine targeting the mucosa of the small intestine~* Use of proton pump inhibitors(Nexium, Prilosec).~* Stool sample with occult blood at baseline exam

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- Low Dose VXA-A1.1 Oral Vaccine (Type: EXPERIMENTAL): Two doses of replication incompetent adenovirus vaccine given in an oral tablet formulation.
- VXA Placebo Tablet (Type: PLACEBO_COMPARATOR): Oral tablets of the same size and number as the vaccine tablet doses. Placebo arms were included during enrollment of each of the experimental dose groups to maintain the double-blind study design.
- Medium Dose VXA-A1.1 Oral Vaccine (Type: EXPERIMENTAL): Two doses of replication incompetent adenovirus vaccine given in an oral tablet
- High Dose VXA-A1.1 Oral Vaccine (Type: EXPERIMENTAL): One dose of replication incompetent adenovirus given in an oral tablet dose. This dose was studied under protocol VXA02-003.

Based on this trial design, predict the completion outcome and termination type (if applicable).